(NewsDirect)
Willow Bioscience CEO Dr Chris Savilejoined Steve Darling from Proactive to announce a groundbreakingdevelopment in the pharmaceutical industry.
Savile shared the company'sachievement in creating a cost-effective process for producingcorticosteroids using their innovative BioOxi platform. This novelapproach to efficient bio-hydroxylation has the potential torevolutionize corticosteroid manufacturing.
Corticosteroids are widely used for theiranti-inflammatory and immunosuppressant properties, making themessential drugs in medical practice. With the corticosteroid marketprojected to grow to $5.93 billion by 2026, ensuring a stable supplychain is crucial. However, a significant portion of corticosteroidproduction occurs outside the United States, leading to potentialsupply chain vulnerabilities and shortages for drug manufacturers.
Savile explained that WillowBioscience's BioOxi process represents a significant advancementby substantially reducing the production costs of corticosteroids.This breakthrough is anticipated to make domestic manufacturing morecompetitive, encouraging the onshoring of corticosteroid productionand reducing supply chain risks.
Ifgranted, the patent protection for this process could offer aremarkable competitive advantage to pharmaceutical manufacturingpartners.
The development of acost-effective corticosteroid manufacturing process highlights WillowBioscience's commitment to innovation and addressing criticalchallenges in the pharmaceutical industry. By leveraging its BioOxiplatform, the company is not only transforming manufacturing practicesbut also contributing to the security and availability of essentialmedications for patients worldwide.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.